Related Experiment Video

Updated: Feb 19, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.5K

Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer

Haipeng Lei1, Chu-Xia Deng1

  • 1Faculty of Health Sciences, University of Macau, Macau SAR, China.

International Journal of Biological Sciences
|November 7, 2017
PubMed

Insights

Mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are linked to various cancers. This review explores FGFR2

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Fibroblast Growth Factor Receptor 2 (FGFR2) is a key signaling receptor tyrosine kinase.
  • FGFR2 mutations are frequently detected in multiple human cancers, including breast, lung, gastric, uterine, and ovarian cancers.
  • The precise role of FGFR2 mutations in cancer development remains incompletely understood.

Purpose of the Study:

  • To elucidate the potential interactions between FGFR2 signaling pathways and major cellular pathways implicated in tumorigenesis.
  • To explore the specific mechanisms by which aberrant FGFR2 signaling may drive breast cancer development.
  • To review recent advancements in therapeutic strategies targeting FGFR2 activity for cancer treatment.

Main Methods:

  • Literature review and analysis of existing studies on FGFR2 mutations and signaling pathways.
  • Exploration of molecular interactions and pathway crosstalk involving FGFR2.
  • Synthesis of current research on FGFR2-targeted therapies.

Main Results:

  • Aberrant FGFR2 signaling may contribute to breast cancer development through interactions with critical oncogenic pathways.
  • Specific FGFR2 mutations are associated with increased cancer risk and progression.
  • Emerging therapies demonstrate potential in inhibiting FGFR2 activity.

Conclusions:

  • FGFR2 plays a significant role in tumorigenesis, particularly in breast cancer, via aberrant signaling.
  • Targeting FGFR2 offers a promising therapeutic avenue for various cancers.
  • Further research is warranted to fully understand FGFR2's role and optimize targeted therapies.
Keywords:
Breast cancerFGFR2inhibitor.mutationpolymorphism

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

5.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.7K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.7K